Prevention of Cardiovascular Events by Antiplatelet Agents After Acute Coronary Syndrome (AReMIS)

This study is currently recruiting participants. (see Contacts and Locations)
Verified July 2014 by AstraZeneca
Sponsor:
Information provided by (Responsible Party):
AstraZeneca
ClinicalTrials.gov Identifier:
NCT01952392
First received: August 21, 2013
Last updated: July 29, 2014
Last verified: July 2014

August 21, 2013
July 29, 2014
October 2013
December 2015   (final data collection date for primary outcome measure)
  • Medical information [ Time Frame: At baseline visit ] [ Designated as safety issue: No ]
    History of coagulation and vascular disorders History of cerebrovascular accidents Cardiovascular risk factors
  • Drug exposure [ Time Frame: Current ] [ Designated as safety issue: No ]
    Current exposure: within 24 hours (before date of recurrent MI). Exposure to clopidogrel, ticagrelor, prasugrel, aspirin, other antiplatelet drugs.
  • Drug exposure [ Time Frame: Recent ] [ Designated as safety issue: No ]
    Recent exposure: in the week (7 days) preceding the recurrent MI. Exposure to clopidogrel, ticagrelor, prasugrel, aspirin, other antiplatelet drugs.
  • Drug exposure [ Time Frame: Past ] [ Designated as safety issue: No ]
    Past exposure: more than a week (7 days) before the recurrent MI and until the ACS index. Exposure to clopidogrel, ticagrelor, prasugrel, aspirin, other antiplatelet drugs.
Same as current
Complete list of historical versions of study NCT01952392 on ClinicalTrials.gov Archive Site
Other medical events of interest [ Time Frame: During follow-up (up to 12 months) ] [ Designated as safety issue: Yes ]
rMI, stroke, bleeding, death
Same as current
Not Provided
Not Provided
 
Prevention of Cardiovascular Events by Antiplatelet Agents After Acute Coronary Syndrome
Study on the Prevention of Cardiovascular Events by Antiplatelet Agents After Acute Coronary Syndrome

Prevention of cardiovascular events by antiplatelet agents after acute coronary syndrome

AReMIS (Antiplatelet and Recurrent Myocardial Infarction Study) To compare the relative risk of new myocardial infarction (recurrent myocardial infarction or 'rMI') in patients with a history of acute coronary syndrome ('ACS': unstable angina or myocardial infarction), using ticagrelor, clopidogrel or prasugrel (if applicable) or none of these treatments, where aspirin is considered a covariate.

Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Probability Sample

Patients aged 18 years or more, both genders,with an acute coronary syndrome, agreed to participate and able to respond to an interview in French and/or providing the details of an alternative replier (proxy) if necessary.

Acute Coronary Syndrome
Not Provided
  • Control group
    Patients aged 18 years or more with an acute coronary syndrome, agreed to participate and able to answer an interview in French and/or providing the details of an alternative replier (proxy) if necessary
  • Case group
    Patients aged 18 years or more with a history of acute coronary syndrome (i.e. a recurrent MI after myocardial history or unstable angina), agreed to participate and able to answer an interview in French and/or providing the details of an alternative replier (proxy) if necessary
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
3750
December 2015
December 2015   (final data collection date for primary outcome measure)

Inclusion Criteria:

Patients aged 18 years or more, both genders, with an acute coronary syndrome (ACS), agreed to participate and able to respond to an interview in French and/or providing the details of an alternative replier (proxy) if necessary.

No Exclusion Criteria.

Both
18 Years and older
No
Contact: Florence Thomas +33141294025 ClinicalTrialTransparency@astrazeneca.com
France
 
NCT01952392
NIS-CFR-BRI-2012/1
Not Provided
AstraZeneca
AstraZeneca
Not Provided
Not Provided
AstraZeneca
July 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP